Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2027-Q2 as of 2026-09-30.
As of 06 Nov 2026, 03:30 pm
For the quarter ended September 30, 2026, Aurobindo Pharma reported a record revenue of ₹10,263 crore (up 24% year-on-year) and a net profit of ₹1,124 crore (up 32.5%). The Board also approved an interim dividend of ₹7 per share.
The record date for the ₹7 per share interim dividend is November 11, 2026. Alongside the financial results, the Board approved a merger scheme for wholly owned subsidiaries Auroactive Pharma Private Limited and Apitoria Pharma Private Limited with the NCLT, Hyderabad.
As of November 5, 2026, the stock closed at ₹1,785, reflecting a +55.3% return over the past year. Technical indicators show a bullish trend on daily, weekly, and monthly timeframes. Key support levels are identified at ₹1,756.33, ₹1,740.47, and ₹1,722.73.
As of 06 Nov 2026, 03:30 pm
Showing 3 of 26 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q2 FY27 and comparative quarterly trends.
| Metric | Q2 FY26 | Q1 FY27 | Q2 FY27(Latest) |
|---|---|---|---|
| Revenue From Operations | ₹8,286 crore | ₹9,150 crore | PEAK₹10,263 crore |
| Profit Before Tax | ₹1,274 crore | ₹1,517 crore | PEAK₹1,691 crore |
| Profit Loss For Period | ₹848 crore | ₹1,032 crore | PEAK₹1,124 crore |
| Basic Earnings Loss Per Share From Continuing And Discontinued Operations | ₹14.61 per share | ₹17.86 per share | PEAK₹19.57 per share |
Q2 FY2026-27 delivered sequential and year-on-year growth in revenue, pre-tax profit and EPS, with revenue at its highest level in the five-quarter series. The quarter’s main counterpoint was negative free cash flow as investing outflows exceeded operating cash flow; property, plant and equipment, work in progress and intangible assets were also higher than at the previous fiscal year-end.
Disclosed bulk and block transactions involving Aurobindo Pharma, shown for the latest 90 days.
Exchange disclosures and regulatory announcements for Aurobindo Pharma.
SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
Aurobindo Pharma Limited has informed the Exchange about Copy of financial results published in newspapers. |SUBJECT: Copy of Newspaper Publication
SERIES:EQ |PURPOSE:INTERIM DIVIDEND - RS 7 PER SHARE |FACE VALUE:1 |RECORD DATE:11-Nov-2026 |BOOK CLOSURE START DATE:- |BOOK CLOSURE END DATE:-
On November 4, 2026, Aurobindo Pharma Limited’s Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026; declared an interim dividend of ₹7.00 per ₹1 equity share; approved filing a merger scheme for wholly owned subsidiaries Auroactive Pharma Private Limited and Apitoria Pharma Private Limited with the NCLT, Hyderabad; approved transferring ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited; and recommended re-appointment of Mangalam Ramasubramanian Kumar as an independent director for a second five-year term from April 1, 2027, subject to member approval by postal ballot. The Board meeting ran from 4:15 p.m. to 6:00 p.m.
Aurobindo Pharma Limited reported consolidated Q2 FY27 results for the quarter ended September 30, 2026: revenue from operations was INR 10,263 crore, up 23.9% year over year; EBITDA before forex and other income was INR 2,156 crore, with a 21.0% margin; and net profit was INR 1,124 crore, up 32.5%. The company also reported final USFDA approvals for 12 products and declared an interim dividend of ₹7.0 per share.
Aurobindo Pharma Limited filed its presentation for the November 5, 2026 investor/analyst call on unaudited results for the quarter and half year ended September 30, 2026. The presentation reports Q2FY27 revenue of ₹10,263 crore, EBITDA of ₹2,156 crore and net profit of ₹1,124 crore, and says the acquisition of Lannett was successfully completed. It also provides updates on biosimilars, biologics contract manufacturing and product filings.
On November 4, 2026, the Board of Directors of Aurobindo Pharma Limited approved an interim dividend of Rs. 7.00 per equity share (equivalent to 700%) for the Financial Year 2026-27. The company has designated November 11, 2026, as the record date for this dividend, with payment scheduled to be made on or before November 20, 2026.
Recent market and company developments associated with Aurobindo Pharma.
Samir Arora-backed Helios Mid Cap Fund added Aurobindo Pharma, Zetwerk, and PVR Inox to its portfolio in October while increasing stakes in Paytm, MCX, and 16 other stocks. The fund exited Park Medi World, expanded its holdings to 77 stocks across 23 sectors, and reported assets under management of Rs 2,421 crore as of October 31, 2026.
Ahead of the Diwali Muhurat trading session on November 8, 2026, Ravi Singh of Master Capital Services Ltd. recommends Aurobindo Pharma, Balkrishna Industries, and Mahindra & Mahindra for long-term investment based on their fundamental strength and potential upside over the next 12 months. The article highlights that Aurobindo Pharma and Balkrishna Industries have set November 11 as the record date for their respective equity dividends, adding a payout opportunity to the stock picks.
More than 50 stocks and investment trusts are scheduled to trade ex-date next week for various corporate actions, including dividends, rights issues, and share buybacks. The combined value of the 51 announced dividend entries totals ₹315.21 per share, with Bayer CropScience declaring the highest individual payout at ₹90 per share.
Aurobindo Pharma reported a 32.5% year-on-year increase in consolidated net profit to ₹1,124 crore for the quarter ended September, driven by a record 24% rise in revenue to ₹10,263 crore. The growth was attributed to strong performance across key markets, with U.S. and European revenues rising 25% and 27% respectively, alongside a declared interim dividend of ₹7 per share.
Indian equity benchmarks extended their winning streak to a fifth consecutive session, with the Nifty 50 closing at 23,961 amid broad-based buying and optimism for a breakout above 24,000. Several companies, including BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma, and NALCO, are in focus as investors track their September-quarter earnings, sales data, and operational updates. Experts advise monitoring support levels around 23,750–23,700 as the bullish trend persists.
Aurobindo Pharma reported a 32.5% rise in net profit to Rs 1,124 crore for the second quarter, while its revenue reached a record high. The company's financial performance for the period was highlighted in recent earnings updates.
Axis Securities presented technical stock picks for the year ahead, assigning buy ratings with specific target prices to multiple listed companies including Aurobindo Pharma Ltd, Hindustan Aeronautics Ltd, IOL Chemicals and Pharmaceuticals Ltd, Jyoti CNC Automation Ltd, Kotak Mahindra Bank Ltd, Karnataka Bank Ltd, Dr Lalpath Labs Ltd, Mayur Uniquoters Ltd, Shivalik Bimetal Controls Ltd, and Sona BLW Precision Forgings Ltd. The analysis also identified Tech Mahindra Ltd and Welspun Living Ltd as having positive momentum structures suggesting upside potential.
Multiple companies including Power Finance Corporation, Container Corporation of India Limited, RITES, and Sonata Software are scheduled to hold board meetings this week to announce Q2FY27 results and potentially approve dividends.
Comprehensive Section Breakdown for Aurobindo Pharma
Strategic Vision: Develops, manufactures, and commercializes generic pharmaceuticals and APIs.
• Global regulatory approvals for manufacturing facilities
• In-house API manufacturing capabilities
• Extensive global commercial infrastructure
Aurobindo Pharma’s revenue from operations rose 12.2% sequentially and 23.9% year on year to ₹10,263 crore in Q2 FY2026-27, the highest in the five-quarter series. Profit before tax increased 11.5% from Q1 to ₹1,691 crore, while profit for the period rose 8.9% to ₹1,124 crore and EPS reached ₹19.57. Operating cash flow was ₹3,283 crore, but investing outflows of ₹3,702 crore left quarterly free cash flow negative at ₹419 crore.
Revenue from operations increased by ₹1,113 crore from ₹9,150 crore in Q1 FY2026-27. It rose in each quarter of the five-quarter series, from ₹8,286 crore in Q2 FY2025-26. Total income, including ₹168 crore of other income, increased 10.8% sequentially to ₹10,432 crore.
Profit before tax was ₹1,691 crore, compared with ₹1,517 crore in Q1 FY2026-27 and ₹1,274 crore in Q2 FY2025-26. Profit for the period was ₹1,124 crore, up from ₹1,032 crore in the previous quarter and ₹848 crore a year earlier. Basic and diluted EPS were ₹19.57, up 9.6% sequentially and 33.9% year on year. Trailing 12-month EPS was ₹68.96.
Total expenses rose 11.2% sequentially to ₹8,741 crore, slightly below the 12.2% increase in revenue from operations. Other expenses increased 14.0% from Q1 FY2026-27 to ₹2,466 crore and were 23.8% higher than in Q2 FY2025-26. Employee benefit expense was ₹1,659 crore, cost of materials consumed was ₹2,980 crore, and depreciation and amortisation expense was ₹531 crore. Finance costs were ₹102 crore, broadly unchanged from the previous quarter.
Tax expense increased 16.7% sequentially to ₹564 crore. Current tax was ₹509 crore, down from ₹610 crore in Q1 FY2026-27, while deferred tax was a charge of ₹55 crore, compared with a credit of ₹127 crore in the prior quarter.
Operating cash flow was ₹3,283 crore; investing and financing activities used ₹3,702 crore and ₹596 crore, respectively. Free cash flow, calculated as operating cash flow plus investing cash flow, was negative ₹419 crore for the quarter.
At 30 September 2026, property, plant and equipment stood at ₹15,292 crore, compared with ₹14,330 crore at 31 March 2026. Capital work in progress was ₹3,487 crore, up from ₹3,009 crore; other intangible assets were ₹3,405 crore, up from ₹2,277 crore; and goodwill was ₹1,269 crore, compared with ₹800 crore.
Cash and cash equivalents were ₹6,232 crore at 30 September 2026, down from ₹7,191 crore at 31 March 2026 but above ₹5,402 crore at 30 September 2025. Other bank balances were ₹3,718 crore, up from ₹2,679 crore at 31 March 2026.
Inventories stood at ₹13,124 crore, compared with ₹12,053 crore at 31 March 2026 and ₹11,192 crore at 30 September 2025. Current trade receivables were ₹7,544 crore, up from ₹7,094 crore at 31 March 2026 and ₹5,891 crore at 30 September 2025.
Category: Manufacturing
Aurobindo Pharma USA Inc (APUSA) is the sales and marketing arm in the US, distributing oral solid dosages and other products through various subsidiaries.
Key Products & Services: Aurolife Pharma LLC • AuroHealth LLC • Acrotech Biopharma Inc • Vespyr Brands, INC. • Aurologistics LLC • Auropackaging LLC
Category: Manufacturing
Aurobindo Pharma operates a full-fledged sales infrastructure in 10 European countries, offering a product portfolio covering various therapeutic segments.
Category: Manufacturing
Eugia Pharma Specialities Ltd. is a subsidiary specializing in general injectables and oncology products, operating globally with multiple manufacturing facilities.
Category: R&D
Aurobindo Pharma has a strong R&D focus with 9 centers dedicated to enhancing patient impact through continuous research.
Core Thesis: The company leverages its in-house API capabilities and global manufacturing and R&D infrastructure to develop and commercialize a wide range of pharmaceutical products.
• Global Manufacturing Footprint: Aurobindo Pharma operates across more than 29 commercial manufacturing and packaging facilities worldwide, with approvals from major regulatory agencies. • Integrated Supply Chain: The company utilizes its own API capabilities and has established logistics hubs and distribution services to support its global operations. • Diverse Product Portfolio: Aurobindo Pharma offers a wide range of generic pharmaceuticals, active pharmaceutical ingredients (API), injectables, and specialty products across various therapeutic areas. • Research and Development Investment: The company maintains a strong R&D focus with multiple centers dedicated to developing new pharmaceutical products and enhancing existing ones.